Cardiovascular safety of NSAIDs

BMJ

Volumn 342, Issue 7789, 2011, Pages 116-

  Ray, Wayne A ^a,b  

^a Division of Pharmacoepidemiology   (United States)

^b Department of Preventive Medicine ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ETORICOXIB; IBUPROFEN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PARACETAMOL; PLACEBO; ROFECOXIB; TANEZUMAB;

CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG MEGADOSE; DRUG SAFETY; EDITORIAL; GASTROINTESTINAL DISEASE; HUMAN; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; LOW DRUG DOSE; META ANALYSIS (TOPIC); MUSCULOSKELETAL DISEASE; PAIN; PRIORITY JOURNAL; SIDE EFFECT;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARDIOVASCULAR DISEASES; HUMANS; RISK FACTORS;

EID: 78751700258     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.c6618     Document Type: Editorial

References (12)

1. Trelle S, Reichenbach S, Wandel S, Hildebrand P, Tschannen B, Villiger PM, et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ 2010;341:c7086.
2. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352:1-11.
3. Solomon SD, McMurray JJV, Pfeffer MA, Witts J, Fowler R, Finn P, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005;352:1-10.
4. Nussmeier NA, Whelton AA, Brown MT, Langford RM, Hoeft A, Parlow JL, et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005;352:11.
5. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000;343:1520-8.
6. Solomon SD, Wittes J, Finn PV, Fowler R, Viner J, Bertagnolli MM, et al. Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials. The CORSS trial safety analysis. Circulation 2008;117:1-10.
7. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase. JAMA 2006;296:1633-44.
8. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2008;00:1-7.
9. Ray WA, Varas-Lorenzo C, Chung CP, Castellsague J, Murray KT, Stein CM, et al. Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease. Circ Cardiovasc Qual Outcomes 2009;2:155-63.
10. Lumley T. Network meta-analysis for indirect treatment comparisons. Stat Med 2002;21:2313-24.
11. MacDonald TM, Wei L. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet 2003;361:573-4.
12. Ray WA, Chung CP, Stein CM, Smalley WE, Arbogast PG, Griffin MR. Risk of peptic ulcer hospitalizations in users of NSAIDs with gastroprotective cotherapy versus coxibs. Gastroenterology 2007;133:790-8.